Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: July 2010
-
By Donald Zuhn — The journal Medical Innovation & Business has devoted its summer issue, which was released last month, to an examination of the effects of patent reform on medical innovation. The periodical has assembled a group of recognizable and respected members of the patent community to tackle various aspects of the topic. …
-
By Kevin E. Noonan — "Politics," according to Otto von Bismarck, "is the art of the possible." And thus it is possible that a patent reform bill will, against all odds, be passed by this session of Congress. But that is only if Senator Patrick Leahy (D-VT) (at right) is successful in sneaking the…
-
By James DeGiulio — Earlier this year, we reported that the European Competitiveness Council unanimously adopted a legislative package designed to create a single EU Patent and EU Patent court (see "Europe Takes Step Closer to Single EU Patent and Patent Court"). However, as noted, EU Patent translations remained a sticking point in the…
-
By Donald Zuhn — Last week, Novartis AG and Novartis Vaccines and Diagnostics, Inc. filed a complaint against U.S. Patent and Trademark Office Director David Kappos, seeking review of the Office's patent term adjustment (PTA) determinations for eleven Novartis patents (see "Court Report," July 11, 2010). The eleven patents specified in the complaint are…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Shire Development Inc. et al. v. Cadila Healthcare Ltd. et al.1:10-cv-00581; filed July 7, 2010 in the District Court of Delaware • Plaintiffs: Shire Development Inc.; Shire Pharmaceutical Development Inc.; Cosmo Technologies Ltd.; Giuliani…
-
By Sarah Fendrick — Last month, the U.S. Patent and Trademark Office published a notice in the Federal Register (75 Fed. Reg. 30773) indicating that it is seeking comments on the collection of information through the use of applicant surveys. The USPTO collects information from the applicant community through surveys to forecast the number…
-
July 19-20, 2010 – Hatch-Waxman Boot Camp*** (American Conference Institute) – Boston, MA July 22, 2010 – "Protect Your Patents from Inequitable Conduct Charges" (Technology Transfer Tactics) – 1:00 – 2:30 PM (EDT) July 26-27, 2010 – Advanced Patent Prosecution Workshop 2010: Claim Drafting & Amendment Writing (Practising Law Institute) – New York, NY July…
-
The Institute for International Research (IIR) will be holding its 2nd Annual Business of Biosimilars conference from September 20-22, 2010 in Boston, MA. The conference will allow attendees to: • Navigate worldwide regulatory and legislative issues;• Build strategic partnerships with emerging markets;• Adopt effective IP and patent protection strategies for biosimilars;• Evaluate scientific implications of…
-
By James DeGiulio — Sanofi, Abbott Successfully Request Sanctions against Glenmark in Tarka Dispute Sanofi and Abbott were successful in their request for sanctions against Glenmark in their patent suit over Tarka, after it was found that Glenmark destroyed evidence relevant to the impending litigation. The dispute began in October 2007, when Glenmark notified…
-
By Devanand Crease — The much anticipated ruling in Monsanto Technology v Cefetra (Case C-428/08) has now issued and confirms the earlier indications that within the European Union (EU) patent protection for gene sequences only extends to material in which the patented gene is actually performing its function. In Monsanto's case (European Patent No.…
Patent Docs 